Supplemental material
Journal of Enzyme Inhibition and Medicinal Chemistry
Volume 33, 2018 - Issue 1
Related Research Data
Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Source:
HAL CCSD
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Source:
Oxford University Press (OUP)
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Source:
Elsevier BV
Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: Novel sulfamoylcarbamates and sulfamides derived from acetophenones
Source:
Elsevier BV
MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond.
Source:
Bentham Science Publishers Ltd.
Thioflavine T fluorescence with β/A4 peptides
Source:
Wiley
Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.
Source:
Springer Science and Business Media LLC
Cholinesterases: new roles in brain function and in Alzheimer's disease.
Source:
Springer Science and Business Media LLC
The Development of Small Molecule Inhibitors of Glutaminyl Cyclase and Isoglutaminyl Cyclase for Alzheimer's Disease
Source:
Wiley
Design, synthesis, in vitro and in vivo evaluation of tacrine–cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease
Source:
Royal Society of Chemistry (RSC)
A review on Alzheimer's disease pathophysiology and its management: an update
Source:
Springer Science and Business Media LLC
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Source:
Elsevier BV
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Source:
Elsevier BV
Investigational drugs in Alzheimer's disease: current progress.
Source:
Informa UK Limited
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease.
Source:
Taylor & Francis
Linking provided by
